5.65%GE 20.37 5.56%QQQQ 34.01 6.00%
Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
THOUSAND OAKS, Calif. - Biotechnology company Amgen Inc. said Business Wire erroneously released a statement from the company Monday, saying the Food and Drug Administration approved its Nplate treatment for a rare type of blood-platelet deficiency condition.
| AMGN | 56.17 |  -2.72 |
In a separate statement, Business Wire said it prematurely issued the press release.
The drug is in fact still under review by the FDA and the company expects a decision by July 23.
The company said its announcement about the FDA approval, which was released Monday morning, was incorrectly distributed.
Nplate is designed to treat the autoimmune disorder chronic immune thrombocytopenic purpura, in which the number of platelets in a person's blood declines, leading to serious bleeding.
The Obama campaign launched a campaign ad, short documentary and web site attacking Republican presidential nominee John McCain's judgment a...
Vice presidential debate surveys after Thursday's debate overall show Gov. Sarah Palin lost the debate with Sen. Joe Biden. But why a loss a...
Republicans John McCain and Sarah Palin on Friday played up her debate performan...
|
Professional Website Design For Corporate - Get a Free Quote Today
Partners  
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
